Can an adult patient with a history of migraines and a pre-existing mental health condition, such as depression or anxiety, take Ubrelvy (Ubrogepant) with Luvox (Fluvoxamine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Ubrelvy Be Given With Luvox?

No, Ubrelvy (ubrogepant) should not be taken with Luvox (fluvoxamine) without dose adjustment, and specifically, patients taking fluvoxamine should not take a second dose of Ubrelvy within 24 hours. 1

Critical Drug Interaction Warning

The FDA-approved prescribing information for Ubrelvy explicitly lists fluvoxamine as a medication that requires special dosing considerations 1:

  • Patients taking fluvoxamine should NOT take a second dose of Ubrelvy within 24 hours 1
  • Fluvoxamine is a moderate-to-potent CYP3A4 inhibitor, which significantly affects ubrogepant metabolism 1, 2
  • Fluvoxamine is specifically identified as a potent inhibitor of CYP1A2 and a moderate inhibitor of CYP3A4 2

Dosing Algorithm When Combining These Medications

If the patient must take both medications:

  1. Initial dose: A single dose of Ubrelvy can be given 1
  2. Second dose restriction: Do NOT allow a second dose of Ubrelvy within 24 hours if the patient is taking fluvoxamine 1
  3. Alternative approach: Consider using the patient's first dose of Ubrelvy only, without the option for a second dose 1

Mechanism of Interaction

  • Fluvoxamine inhibits CYP3A4 and CYP1A2 enzymes, which are involved in ubrogepant metabolism 1, 2
  • This inhibition increases ubrogepant exposure in the bloodstream, raising the risk of adverse effects 1
  • The interaction is significant enough to warrant explicit FDA labeling restrictions 1

Clinical Context for This Patient

For an adult with migraines and depression/anxiety:

  • Fluvoxamine is an effective SSRI for anxiety disorders and OCD, with demonstrated efficacy in multiple anxiety conditions 2
  • Ubrelvy is a CGRP receptor antagonist approved for acute migraine treatment with or without aura 3, 1, 4
  • The 2025 American College of Physicians guideline identifies CGRP antagonists (gepants like ubrogepant) as options for patients who don't respond to triptans with NSAIDs 3

Common Pitfalls to Avoid

  • Do not assume all migraine medications are safe with fluvoxamine - this specific interaction requires dose limitation 1
  • Do not allow patients to take a rescue second dose if they're on fluvoxamine, even if the first dose was ineffective 1
  • Counsel patients explicitly about the 24-hour restriction on second doses when prescribing this combination 1

Alternative Considerations

If frequent dosing of Ubrelvy is needed:

  • Consider switching from fluvoxamine to an SSRI with less CYP3A4 inhibition (though this requires psychiatric consultation) 5, 2
  • Consider alternative acute migraine treatments such as triptans with NSAIDs, which don't have this interaction 3
  • Ensure the patient isn't taking other CYP3A4 inhibitors concurrently (verapamil, cyclosporine, ciprofloxacin, fluconazole) 1

Safety Monitoring

  • Monitor for ubrogepant adverse effects: nausea, somnolence, dry mouth, and oropharyngeal pain 4, 6
  • Watch for allergic reactions, which can occur hours to days after taking Ubrelvy 1
  • Ensure patients understand they should not exceed 8 migraine treatments with Ubrelvy in 30 days 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ubrogepant to Treat Acute Migraine in Adults.

Neurology international, 2021

Guideline

Switching from Citalopram to Sertraline

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Ubrogepant for the Treatment of Migraine.

The New England journal of medicine, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.